Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease

NCT00277602 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00277602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00277602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
November 30, 1999
Completion date
July 31, 2004
Enrollment
537 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease